Presentation is loading. Please wait.

Presentation is loading. Please wait.

Module 3 Evaluation unit TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug.

Similar presentations


Presentation on theme: "Module 3 Evaluation unit TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug."— Presentation transcript:

1 Module 3 Evaluation unit TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 3 Evaluation unit

2 Learning objectives By the end of this module, you should understand:  How to define a survey area, known as an evaluation unit (EU). Slide 2

3 Module 3 Evaluation unit Overview  Survey area for a TAS  Defining an EU  Combining IUs  Dividing IU  Geographical area of an EU Slide 3

4 Module 3 Evaluation unit Survey area for a TAS  If all the data from relevant IUs confirm that they are eligible for a TAS, planning can begin.  The first step in designing a TAS is to define the survey area. Slide 4 Cluster-based sampling Systematic sampling Census SchoolCommunity Sample size and critical cut-off Evaluation unit 1. Survey area 2. Survey site 3. Sampling strategy 4. Sample size

5 Module 3 Evaluation unit Slide 5  Implementation unit (IU): The administrative unit in a country used for MDA  Evaluation unit (EU): An area selected for a TAS Survey area for a TAS

6 Module 3 Evaluation unit Defining an EU Slide 6 IUs within an EU can be combined, divided or remain the same, but all IUs in a country in which MDA is conducted must be included in a TAS.  IUs in an EU are usually contiguous.  All IUs in an EU should have had at least five effective rounds of MDA (i.e. ≥ 65% total population) and meet all the eligibility criteria for conducting a TAS.  All areas in the EU should have similar epidemiological features and LF transmission dynamics (e.g. epidemiological drug coverage, baseline prevalence, prevalence of Mf or Ag in sentinel and spot- check sites, principal parasites, vector abundance).  The population should not exceed 2 million.

7 Module 3 Evaluation unit Combining IUs Endemic IU MDA 1 2 3 Unit Total population Baseline Mf prevalence (%) MDA coverage (%) Sentinel site Mf prevalence (%) (after fifth round) Spot-check site Mf prevalence (%) #1#2#3#4#5 132 9832.181697976 00 2101 4383.478677772760.30.1 352 1382.975707276680.1 Slide 7

8 Module 3 Evaluation unit Dividing an IU Slide 8 Total population Baseline Mf prevalence (%) MDA coverage (%) Sentinel site Mf prevalence (%) (after fifth round) Spot-check site Mf prevalence (%) #1#2#3#4#5 2 647 9532.879667174720.20.3 1 2 3 Sub-districtTotal population Baseline Mf prevalence (%) 1798 2341.8 2989 4365.4 3860 2831.2 Endemic IU MDA

9 Module 3 Evaluation unit Slide 9  Although there is no upper limit to the geographical area of an EU, the following considerations should be taken into account when combining IUs:  The probability that foci of infection will be missed increases as the geographical area of the EU increases.  Covering a larger area during the survey may increase logistical requirements (e.g. transport costs). Geographical area of an EU

10 Module 3 Evaluation unit Exercise Slide 10 Using existing data (e.g. maps, list of IUs, population sizes, number of rounds of MDA and coverage). 1.Define an appropriate EU(s). Note: Some of the data will have been reported on the ‘ELIGIBILITY’ worksheet of the TAS Eligibility and Reporting Form 2.Present the defined EU(s) to the group.


Download ppt "Module 3 Evaluation unit TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug."

Similar presentations


Ads by Google